Tadalafil 5 mg once‐daily therapy for men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: Results from a randomized, double‐blind, placebo‐controlled trial carried out in Japan and Korea
- 27 February 2014
- journal article
- research article
- Published by Wiley in International Journal of Urology
- Vol. 21 (7) , 670-675
Abstract
Objectives: To gain further evidence on the efficacy, safety and tolerability of tadalafil 5 mg once‐daily in Asian men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.Methods: Japanese and Korean men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia were randomized to once‐daily tadalafil 5 mg (n = 306) or placebo (n = 304) for 12 weeks.Results: A significantly greater improvement (P < 0.001) in total International Prostate Symptom Score for the change from baseline (week 0) to study end‐point (week 12) was observed for tadalafil (−6.0) versus placebo (−4.5). Significantly greater improvements (P < 0.01) in total International Prostate Symptom Score for the change from baseline to weeks 4 and 8 were observed for tadalafil versus placebo. Significantly greater improvements (P < 0.05) in International Prostate Symptom Score voiding and storage subscores, and International Prostate Symptom Score Quality of Life Index were observed for the change from baseline to end‐point for tadalafil versus placebo. Significantly greater improvements (P < 0.001) in urinary symptoms were observed for tadalafil versus placebo for both Patient and Clinician Global Impressions of Improvement. No new safety concerns were identified.Conclusions: These findings confirm the efficacy and safety profile of tadalafil 5 mg once‐daily in Asian men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.Keywords
This publication has 17 references indexed in Scilit:
- EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic ObstructionEuropean Urology, 2013
- Efficacy and Safety of Tadalafil Once Daily in the Treatment of Men With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: Results of an International Randomized, Double-Blind, Placebo-Controlled TrialEuropean Urology, 2011
- National-wide data on the treatment of BPH in KoreaProstate Cancer and Prostatic Diseases, 2011
- Tadalafil Administered Once Daily for Treatment of Lower Urinary Tract Symptoms in Korean men with Benign Prostatic Hyperplasia: Results from a Placebo‐Controlled Pilot Study Using Tamsulosin as an Active ControlLUTS: Lower Urinary Tract Symptoms, 2011
- Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Pathophysiology and mechanism(s) of actionNeurourology and Urodynamics, 2011
- Efficacy and safety of dutasteride in Japanese men with benign prostatic hyperplasiaInternational Journal of Urology, 2009
- Tadalafil Relieves Lower Urinary Tract Symptoms Secondary to Benign Prostatic HyperplasiaJournal of Urology, 2007
- Silodosin, a new α 1A ‐adrenoceptor‐selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo‐controlled, double‐blind study in Japanese menBJU International, 2006
- Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasiaBJU International, 2005
- Prevalence of Prostatism in Japanese Men in a Community-based Study with Comparison to a Similar American StudyJournal of Urology, 1995